Back to Research Platform
Immune
✓ Janoshik Verified

Thymosin Alpha-1

Also known as: TA1

Molecular Weight

3108 Da

Half-Life

2 hours

Evidence Passport

Thymosin Alpha-1

Evidence strength, status, identity, route and safety are scored separately.

Reviewed 2026-08-31

Human evidence

Confirmatory human evidence

Phase 3 evidence is recorded, but the exact indication and study population still matter.

Development status

Phase 3 development or evidence

Investigational development is not the same as approval or product suitability.

Identity match

Named compound linked

Sources are linked to the named compound; formulation and product quality remain separate questions.

Route relevance

Route match not verified

Catalogue route: Subcutaneous injection. A matching human study route is not confirmed.

Safety record

5 documented flags

Documented flags are visible, but absence of a listed risk would not prove safety.

What is still missing?
  • The exact studied route and protocol have not been verified in the source record.

3 app-verified sources linked · Version 2026-08-31

Compare the evidence

Mechanism of Action

A 28-amino acid immunomodulating polypeptide that stimulates both innate and adaptive immune responses. Activates Toll-like receptors and downstream signaling pathways. Restores immune homeostasis and enhances T-cell function, dendritic cell maturation, and cytokine production.

Research areas reported in source material

These topics describe the catalogue's research index. They are not promised outcomes or personal recommendations.

  • Enhanced immune function via TLR activation
  • Improved vaccine response
  • Anti-viral properties (HIV, hepatitis)
  • Reduced inflammation
  • Synergistic with chemotherapy for anti-tumor response

Safety & Risks

  • Injection site reactions
  • Rare allergic reactions

Contraindications:

  • Organ transplant recipients
  • Autoimmune conditions requiring immunosuppression

Notable Research

Thymosin alpha-1 in hepatitis B treatment (2008)

Demonstrated antiviral efficacy in chronic hepatitis B patients

DOI: 10.1016/j.jhep.2008.03.023

Explore more peptides in this category

View All Immune Peptides →

Research Disclaimer: This information is compiled from published research and is provided for educational purposes only. Peptides discussed here are classified as research chemicals in most jurisdictions and are not FDA-approved for human use unless otherwise noted. Consult a qualified healthcare provider before starting any protocol.